Blood biomarkers in breast cancer
- Submission status
- Closed
- Submission deadline
Identification and validation of non-invasive blood biomarkers open new perspectives on breast cancer diagnosis, treatment and follow-up. These biomarkers, which range from small fragmented single DNA molecule to circulating cell clusters, are commonly referred to as “liquid biopsy”. Their development has been first driven by technological progresses in both sequencing and microfluidics, while the use of artificial intelligence is now helping move forward large dataset and multi-omics analyses. The implementation into the clinics remains a long issue for most biomarkers, with a balance to be kept between formal by-the-book lengthy randomized clinical trials versus a direct implementation with no demonstrated clinical utility. We welcome in this collection of npj Breast Cancer original articles, perspectives, and reviews addressing these key technological and clinical aspects applied to blood biomarkers in breast cancer.
This Collection supports and amplifies research related to SDG 3.
Editors
-
François-Clément Bidard
Institut Curie & UVSQ / Université Paris-Saclay, Paris, France
-
Jorge S Reis-Filho
Memorial Sloan Kettering Cancer Center, NY, USA
All articles have undergone npj Breast Cancer's standard peer review process and have been subject to all the journal’s standard policies. This includes the journal’s policy on competing interests. The Editors declare no competing interests with the submissions which they have handled through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.
If accepted for publication, an article processing charge (with standard waiver policy). If your institution or country has an open access agreement with Springer Nature, you may publish your article OA at no cost or in some cases with the costs partially funded (see details here).
All Collections are open for submissions from all authors – and not by invitation only – on the condition that the manuscripts fall within the scope of the Collection and of npj Breast Cancer more generally.
Manuscripts submitted to an open Collection may be considered unsuitable for inclusion, particularly if they fall outside the scope of the Collection. In such cases, the authors will be notified by the editorial office and their manuscript can be considered as a regular npj Breast Cancer submission.
npj Breast Cancer’s in-house editors reserve the right to assume responsibility for the management of a Collection at any stage.
